Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Rossig, Claudia  [Clear All Filters]
2014
Leuchte K, Altvater B, Hoffschlag S, Potratz J, Meltzer J, Clemens D, Luecke A, Hardes J, Dirksen U, Juergens H, et al. Anchorage-independent growth of Ewing sarcoma cells under serum-free conditions is not associated with stem-cell like phenotype and function. Oncol Rep. 2014.
Ehlert K, Rossig C, Groll AH, Beyna T, Froehlich B, Juergens H. Diffuse Hemorrhagic Colitis in a Patient With Dyskeratosis Congenita After Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation. J Pediatr Hematol Oncol. 2014.
2018
Rauwolf K, Herbrüggen H, Zöllner S, Thorer H, Makarova O, Kaiser T, Pettke A, Rossig C, Burkhardt B, Groll AH. Durable control of Hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic hematopoietic stem cell transplantation. J Viral Hepat. 2018.
2019
Linke C, Ehlert K, Ahlmann M, Fröhlich B, Mohring D, Burkhardt B, Rossig C, Groll AH. Epidemiology, Utilization of Health Care Resources, and Outcome of Invasive Fungal Diseases following Pediatric Allogeneic Hematopoietic Stem Cell Transplantation. Mycoses. 2019.
2020
Reinke E, Jürgens H, Haier J, Froehlich B, Kontny U, Rossig C. [Trans-Sectoral Patient Care in Pediatric Oncology: Quality Assurance by Novel Reimbursement Models for Outpatient Services]. Klin Padiatr. 2020.
2021
Schliemann C, Kessler T, Berdel AF, Hemmerle T, Angenendt L, Altvater B, Rossig C, Mikesch J-H, Lenz G, Schäfers M, et al. Phase I study of F16IL2 antibody-cytokine fusion with very low-dose araC in acute myeloid leukaemia relapse after allogeneic stem cell transplantation. Br J Haematol. 2021.
2023
Bader P, Rossig C, Hutter M, Ayuk FAyuketang, Baldus CD, Bücklein VL, Bonig H, Cario G, Einsele H, Holtick U, et al. CD19-CAR-T cells are an effective therapy of post-transplant relapse in B- ALL patients: Real-World Data from Germany. Blood Adv. 2023.
Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, H Vormoor J, Calkoen FG, Locatelli F, Del Bufalo F, et al. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. J Clin Oncol. 2023:JCO2301314.
Winestone LE, Bhojwani D, Ghorashian S, Muffly L, Leahy ABarz, Chao K, Steineck A, Rossig C, Lamble A, Maude SL, et al. INSPIRED Symposium Part 4A: Access to CAR T cell Therapy in Unique Populations with B-cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2023.